Opicapone for the treatment of Parkinson’s disease

@article{Rodrigues2017OpicaponeFT,
  title={Opicapone for the treatment of Parkinson’s disease},
  author={Filipe Brogueira Rodrigues and Joaquim J. Ferreira},
  journal={Expert Opinion on Pharmacotherapy},
  year={2017},
  volume={18},
  pages={445 - 453}
}
ABSTRACT Introduction: Parkinson’s disease (PD) is a progressive neurodegenerative disease. The currently available treatment options only have a symptomatic effect. With disease progression almost all antiparkinsonian pharmacological classes are tried, but the gold standard of pharmacological management is still L-dopa. Various strategies can be used to raise the dopaminergic tone. Catechol-O-methyltransferase (COMT) inhibitors attain this goal by decreasing L-dopa peripheral metabolism. Areas… 
Opicapone for the treatment of Parkinson’s disease: an update
TLDR
This article summarizes knowledge about a new third-generation COMT inhibitor, namely opicapone (OPC) (Search period: 2016–2019), and details the pharmacological profile of OPC and the results of completed clinical trials.
Emerging Pharmacotherapies for Motor Symptoms in Parkinson’s Disease
TLDR
Existing and emerging pharmacotherapies for motor symptoms in PD are outlined and newer medications and modes of delivery continue to be researched and added to the therapeutic armamentarium.
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease
TLDR
This study provides Class III evidence that for patients with Parkinson disease and end-of-dose motor fluctuations, long-term use of opicapone is well tolerated and reduces “off” time.
A Stage-Based Approach to Therapy in Parkinson’s Disease
TLDR
A practical, stage-based guide to pharmacological management of both motor and non-motor symptoms of PD is provided, to help the physician in yielding the best therapeutic strategies for each symptom and condition in patients with PD.
Safety and Tolerability of Pharmacotherapies for Parkinson’s Disease in Geriatric Patients
TLDR
Geriatric patients with Parkinson’s disease experience a specific profile of comorbidities and an international register concerning issues of safer drug application and monitoring could help to implement a better treatment.
Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson’s disease
  • J. Finberg
  • Medicine
    Journal of Neural Transmission
  • 2018
TLDR
The scientific background to the localization and function of the enzymes, the physiological changes resulting from their inhibition, and the basic and clinical pharmacology of the various inhibitors and their role in treatment of Parkinson’s disease are described.
Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping.
TLDR
Opicapone, in the rat, was found to be rapidly absorbed, widely distributed to peripheric tissues, metabolized mainly via conjugative pathways at the nitro catechol ring, and primarily excreted via feces.
Opicapone Protects Against Hyperhomocysteinemia-Induced Increase in Blood-Brain Barrier Permeability.
TLDR
Results show that Opicapone protects against HHcy-induced BBB permeability by reducing the expression and gelatinase activity of MMPs, and increasing the expression of claudin-2.
Cellular phenotypes as inflammatory mediators in Parkinson's disease: Interventional targets and role of natural products.
TLDR
The role of cellular phenotypes as a skew that favors PD progression is put together and the lack of experimental approaches and challenges that affects understanding the cellular targets that can be used against natural derivatives in alleviating PD pathophysiology are discussed.
A Screening Strategy for Evaluation of Drug Transport across the Blood-Brain Barrier: Application to Catechol-O-methyltransferase Inhibitors, Dopamine β-hydroxylase Inhibitors and Dibenz[b,f]azepine-5-carboxamide Derivatives
Tese de doutoramento em Ciencias farmaceuticas, na especialidade de Farmacologia e Farmacoterapia, apresentada a Faculdade de farmacia da Universidade de Coimbra
...
1
2
...

References

SHOWING 1-10 OF 92 REFERENCES
Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
TLDR
In the management of the motor complications seen in Parkinson's disease, tolcapone and entacapone can be used to reduce off time, reduce levodopa dose, and modestly improve motor impairment and disability.
New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.
TLDR
Preclinical and clinical studies have shown that COMT inhibitors markedly enhance levodopa availability and prolong its plasma half-life, and COMT inhibition promises to become an important means of extending the benefits oflevodopa therapy in PD.
Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial
TLDR
Treatment with a 50-mg once-daily dose of opicapone was associated with a significant reduction in mean daily off-time in levodopa-treated patients with PD and motor fluctuations, and this effect is maintained for at least 1 year.
Efficacy and safety of opicapone, a new COMT-inhibitor, for the treatment of motor fluctuations in Parkinson's Disease patients: BIPARK-II study
TLDR
OPC is a promising new COMT inhibitor and deserves further clinical evaluation in larger samples of patients with PD on levodopa treatment with motor fluctuations, but the exploratory analysis performed shows improvement in various motor outcomes.
Effect of moderate liver impairment on the pharmacokinetics of opicapone
TLDR
The bioavailability of an orally administered single dose of 50 mg OPC was significantly higher in patients with moderate chronic hepatic impairment, perhaps by a reduced first-pass effect.
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial
TLDR
A randomised, double-blind, placebo-controlled and active-controlled trial of opicapone as an adjunct to levodopa in patients with Parkinson's disease with end-of-dose motor fluctuations, finding that treatment with opiapone 50 mg was superior to placebo.
New treatments for levodopa‐induced motor complications
TLDR
Randomized controlled trials conducted in patients suffering from already established complications showed that new levodopa (l‐dopa) formulations such as intrajejunal l‐dop–carbidopa infusion and bilayered extended‐release l‐Dopa–car bidopa (IPX066) can improve motor fluctuations.
Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor Fluctuations
TLDR
Tolcapone was effective at prolonging the clinical benefit oflevodopa and reducing total levodopa requirements in PD patients with motor fluctuations, and was well tolerated.
Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
TLDR
Long-term entacapone treatment effectively prolonged the beneficial response to levodopa in parkinsonian patients with the wearing-off phenomenon, and improvement occurred irrespective of the reduction of thelevodopa dose.
Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment
TLDR
Tolcapone appears to be beneficial in the treatment of patients with parkinsonism who have not yet developed motor fluctuations, and these improvements were maintained up to the 12-month assessment.
...
1
2
3
4
5
...